Arena Pharmaceuticals Stock Forecast, Price & News

+1.10 (+1.83 %)
(As of 09/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume897,516 shs
Average Volume487,953 shs
Market Capitalization$3.73 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Arena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Arena Pharmaceuticals logo

About Arena Pharmaceuticals

Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.37 out of 5 stars

Medical Sector

183rd out of 1,350 stocks

Pharmaceutical Preparations Industry

86th out of 664 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

Is Arena Pharmaceuticals a buy right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arena Pharmaceuticals stock.
View analyst ratings for Arena Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Arena Pharmaceuticals?

Wall Street analysts have given Arena Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arena Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Arena Pharmaceuticals?

Arena Pharmaceuticals saw a decline in short interest in the month of August. As of August 13th, there was short interest totaling 2,300,000 shares, a decline of 19.0% from the July 29th total of 2,840,000 shares. Based on an average trading volume of 450,900 shares, the short-interest ratio is presently 5.1 days.
View Arena Pharmaceuticals' Short Interest

When is Arena Pharmaceuticals' next earnings date?

Arena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Arena Pharmaceuticals

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) posted its quarterly earnings data on Wednesday, August, 4th. The biopharmaceutical company reported ($2.40) EPS for the quarter, missing analysts' consensus estimates of ($2.20) by $0.20.
View Arena Pharmaceuticals' earnings history

How has Arena Pharmaceuticals' stock price been impacted by COVID-19?

Arena Pharmaceuticals' stock was trading at $40.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARNA stock has increased by 51.0% and is now trading at $61.05.
View which stocks have been most impacted by COVID-19

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Shares of Arena Pharmaceuticals reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ARNA?

12 analysts have issued twelve-month price targets for Arena Pharmaceuticals' stock. Their forecasts range from $76.00 to $120.00. On average, they anticipate Arena Pharmaceuticals' share price to reach $97.25 in the next year. This suggests a possible upside of 59.3% from the stock's current price.
View analysts' price targets for Arena Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the following people:
  • Amit Dilip Munshi, President, Chief Executive Officer & Director
  • Laurie D. Stelzer, Chief Financial Officer & Executive Vice President
  • Paul D. Streck, Chief Medical Officer & SVP-Clinical Development
  • Douglas J. Manion, Executive Vice President-Research & Development
  • Douglas A. Bakan, Vice President-Technical Operations

What is Amit Munshi's approval rating as Arena Pharmaceuticals' CEO?

16 employees have rated Arena Pharmaceuticals CEO Amit Munshi on Amit Munshi has an approval rating of 66% among Arena Pharmaceuticals' employees.

Who are some of Arena Pharmaceuticals' key competitors?

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), (CGC), Inovio Pharmaceuticals (INO), Cytokinetics (CYTK), Micron Technology (MU), NVIDIA (NVDA), Novavax (NVAX), Alibaba Group (BABA), GW Pharmaceuticals (GWPH) and AT&T (T).

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

Who are Arena Pharmaceuticals' major shareholders?

Arena Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.20%), BlackRock Inc. (9.24%), Avoro Capital Advisors LLC (6.67%), State Street Corp (3.06%), Lord Abbett & CO. LLC (2.64%) and Geode Capital Management LLC (1.76%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Christopher Cabell, Jayson Donald Alexander Dallas, Kevin Robert Lind, Manmeet Singh Soni, Randall E Woods, Robert Lisicki, Robert Lisicki, Steven W Spector, Tina Susan Nova and Vincent Aurentz.
View institutional ownership trends for Arena Pharmaceuticals

Which institutional investors are selling Arena Pharmaceuticals stock?

ARNA stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Lord Abbett & CO. LLC, Goldman Sachs Group Inc., FMR LLC, Marshall Wace North America L.P., Bank of America Corp DE, Rice Hall James & Associates LLC, and Susquehanna International Group LLP. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Amit Munshi, Jayson Donald Alexander Dallas, Robert Lisicki, and Vincent Aurentz.
View insider buying and selling activity for Arena Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Arena Pharmaceuticals stock?

ARNA stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Woodline Partners LP, PFM Health Sciences LP, First Light Asset Management LLC, Integral Health Asset Management LLC, Segall Bryant & Hamill LLC, Great Point Partners LLC, and State Street Corp. Company insiders that have bought Arena Pharmaceuticals stock in the last two years include Amit Munshi, and Jayson Donald Alexander Dallas.
View insider buying and selling activity for Arena Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Arena Pharmaceuticals?

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $61.05.

How much money does Arena Pharmaceuticals make?

Arena Pharmaceuticals has a market capitalization of $3.73 billion and generates $320,000.00 in revenue each year. The biopharmaceutical company earns $-404,730,000.00 in net income (profit) each year or ($7.39) on an earnings per share basis.

How many employees does Arena Pharmaceuticals have?

Arena Pharmaceuticals employs 363 workers across the globe.

When was Arena Pharmaceuticals founded?

Arena Pharmaceuticals was founded in 1977.

What is Arena Pharmaceuticals' official website?

The official website for Arena Pharmaceuticals is

Where are Arena Pharmaceuticals' headquarters?

Arena Pharmaceuticals is headquartered at 6154 Nancy Ridge Drive, San Diego CA, 92121.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at (858) 453-7200 or via email at [email protected].

This page was last updated on 9/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.